Skip to main content
. 2018 Aug 13;18:813. doi: 10.1186/s12885-018-4724-8

Fig. 3.

Fig. 3

Higher levels of CREB3L1 expression in TNBC demonstrate an improved response to doxorubicin-based chemotherapy. a A student t-test (two tailed, two sample unequal variance) was performed to compare CREB3L1 IRS values in tumors responded to doxorubicin-based chemotherapy (RCB Class 0-2, responder) versus those resisted the treatment (RCB Class 3, non-responder). b Pearson analysis was performed to determine the correlation between CREB3L1 IRS values and RCB scores of the tumors. The hollow dot indicates two samples at the same location on the plot. c Percentage of cases with indicated RCB class in tumors with lower expression of CREB3L1 (IRS value 0-3) and those with higher expression of the protein (IRS value 4-12)